Digital Gene Technologies Inc.
This article was originally published in Start Up
Drug Discovery Tools. Functional Genomics. Digital Gene Technologies was founded to exploit technology that it claims can correlate rates of gene expression to progression of disease, in a way that accounts for all the genes in a given tissue sample. DGT uses electrophoresis to compare the tagged mRNA to previous samples in DGT's database, and anomalies in mRNA distribution are identified.
You may also be interested in...
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.